OpenURL Connection Search

Select item for more details and to access through your institution.

Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes.
Published in:
Diabetologia, 2006, v. 49, n. 9, p. 2049, doi. 10.1007/s00125-006-0340-2
By:
- Matikainen, N.;
- Mänttäri, S.;
- Schweizer, A.;
- Ulvestad, A.;
- Mills, D.;
- Dunning, B. E.;
- Foley, J. E.;
- Taskinen, M.-R.
Publication type:
Article
The effect of vildagliptin therapy on atherogenic postprandial remnant particles and LDL particle size in subjects with Type 2 diabetes.
Published in:
Diabetic Medicine, 2013, v. 30, n. 6, p. 756, doi. 10.1111/dme.12094
By:
- Matikainen, N.;
- Taskinen, M.‐R.
Publication type:
Article
Primary aldosteronism: Higher volume load, cardiac output and arterial stiffness than in essential hypertension.
Published in:
Journal of Internal Medicine, 2021, v. 289, n. 1, p. 29, doi. 10.1111/joim.13115
By:
- Choudhary, M. K.;
- Värri, E.;
- Matikainen, N.;
- Koskela, J.;
- Tikkakoski, A. J.;
- Kähönen, M.;
- Niemelä, O.;
- Mustonen, J.;
- Nevalainen, P. I.;
- Pörsti, I.
Publication type:
Article
Apolipoprotein B48 metabolism in chylomicrons and very low-density lipoproteins and its role in triglyceride transport in normo- and hypertriglyceridemic human subjects.
Published in:
2020
By:
- Björnson, E.;
- Packard, C.J.;
- Adiels, M.;
- Andersson, L.;
- Matikainen, N.;
- Söderlund, S.;
- Kahri, J.;
- Hakkarainen, A.;
- Lundbom, N.;
- Lundbom, J.;
- Sihlbom, C.;
- Thorsell, A.;
- Zhou, H.;
- Taskinen, M.‐R.;
- Borén, J.;
- Taskinen, M-R
Publication type:
journal article
Investigation of human apoB48 metabolism using a new, integrated non-steady-state model of apoB48 and apoB100 kinetics.
Published in:
2019
By:
- Björnson, E.;
- Packard, C. J.;
- Adiels, M.;
- Andersson, L.;
- Matikainen, N.;
- Söderlund, S.;
- Kahri, J.;
- Sihlbom, C.;
- Thorsell, A.;
- Zhou, H.;
- Taskinen, M.‐R.;
- Borén, J.;
- Taskinen, M-R
Publication type:
journal article
Adverse effects of fructose on cardiometabolic risk factors and hepatic lipid metabolism in subjects with abdominal obesity.
Published in:
2017
By:
- Taskinen, M.‐R.;
- Söderlund, S.;
- Bogl, L. H.;
- Hakkarainen, A.;
- Matikainen, N.;
- Pietiläinen, K. H.;
- Räsänen, S.;
- Lundbom, N.;
- Björnson, E.;
- Eliasson, B.;
- Mancina, R. M.;
- Romeo, S.;
- Alméras, N.;
- Pepa, G. D.;
- Vetrani, C.;
- Prinster, A.;
- Annuzzi, G.;
- Rivellese, A.;
- Després, J.‐P.;
- Borén, J.
Publication type:
journal article
The increase of apolipoprotein A-V during postprandial lipemia parallels the response of triglyceride-rich lipoproteins in type 2 diabetes: no relationship between apoA-V and postheparin plasma lipolytic activity.
Published in:
2007
By:
- Kahri J;
- Fruchart-Najib J;
- Matikainen N;
- Fruchart J;
- Vakkilainen J;
- Taskinen M;
- Kahri, Juhani;
- Fruchart-Najib, Jamila;
- Matikainen, Niina;
- Fruchart, Jean-Charles;
- Vakkilainen, Juha;
- Taskinen, Marja-Riitta
Publication type:
journal article

Found: 7

Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes.

The effect of vildagliptin therapy on atherogenic postprandial remnant particles and LDL particle size in subjects with Type 2 diabetes.

Primary aldosteronism: Higher volume load, cardiac output and arterial stiffness than in essential hypertension.

Apolipoprotein B48 metabolism in chylomicrons and very low-density lipoproteins and its role in triglyceride transport in normo- and hypertriglyceridemic human subjects.

Investigation of human apoB48 metabolism using a new, integrated non-steady-state model of apoB48 and apoB100 kinetics.

Adverse effects of fructose on cardiometabolic risk factors and hepatic lipid metabolism in subjects with abdominal obesity.

The increase of apolipoprotein A-V during postprandial lipemia parallels the response of triglyceride-rich lipoproteins in type 2 diabetes: no relationship between apoA-V and postheparin plasma lipolytic activity.